Publicaciones en colaboración con investigadores/as de Hospital Universitario San Cecilio (15)

2024

  1. Defining well-being in psoriasis: A Delphi consensus among healthcare professionals and patients

    Scientific Reports, Vol. 14, Núm. 1

  2. Family Planning Concerns Among Women With Psoriasis: A Descriptive, Cross-Sectional, Multicenter Study

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 1, pp. 10-20

  3. Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real-life clinical practice

    Experimental Dermatology, Vol. 33, Núm. 8

  4. Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice

    Journal of the European Academy of Dermatology and Venereology, Vol. 38, Núm. 9, pp. 1783-1790

2023

  1. Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP)

    Actas Dermo-Sifiliograficas

  2. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525

  3. Moderate to Severe Psoriasis in Older Adults: Recommendations on Management from the Psoriasis Working Group of the Spanish Academy of Dermatology and Venereology (AEDV)

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 9, pp. 802-811

  4. Selection of Quality Indicators for the Certification of Psoriasis Units: The CUDERMA Project Delphi Consensus Study

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 10, pp. 865-883

  5. Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results

    Clinical and experimental dermatology, Vol. 48, Núm. 9, pp. 991-997

  6. [Translated article] Updated Position of the Spanish Psoriasis Group (GPs) on the Use of Biosimilar Drugs in Moderate to Severe Psoriasis

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 6, pp. T494-T501

2022

  1. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Dermatologic Therapy, Vol. 35, Núm. 2

2021

  1. A new classification of the severity of psoriasis: What’s moderate psoriasis?

    Life, Vol. 11, Núm. 7

2020

  1. The effectiveness and safety of ixekizumab in psoriasis patients under clinical practice conditions: A Spanish multicentre retrospective study

    Dermatologic Therapy, Vol. 33, Núm. 6

2017

  1. Modelos de atención multidisciplinar en pacientes con artritis psoriásica en España

    Reumatologia Clinica, Vol. 13, Núm. 2, pp. 85-90

2013

  1. Adherence and patient satisfaction with topical treatment in psoriasis, and the use, and organoleptic properties of such treatments: A delphi study with an expert panel and members of the psoriasis group of the spanish academy of dermatology and venereology

    Actas Dermo-Sifiliograficas, Vol. 104, Núm. 6, pp. 488-496